Regulators across the bloc are quietly bracing for the biggest shake-up of medicines rules in two decades, and the pressure is now landing on the agency that has to make it work. At its June 2026 meeting, the management board of the European Medicines Agency (EMA) reported that preparations for the new pharmaceutical legislation are advancing across multiple delivery streams, aligned with the Commission’s parallel work on the delegated and implementing acts that will give the reform teeth.
The headline change is speed. The new regulation cuts the standard EMA scientific assessment timeline from 210 days to 180, with an accelerated pathway compressing it further to 150 days for medicines that meet an urgent unmet need. For patients waiting on novel therapies, faster approvals sound like an unambiguous win. For the regulatory network, they are a logistical challenge: shorter clocks mean less time for the back-and-forth between assessors and companies that has long been used to resolve doubts about safety and efficacy.
To manage that, the agency’s oversight group has endorsed a network collaboration model designed to pull in experts from national regulators across the EU from the outset rather than concentrating the burden in a handful of large agencies. The logic is sound. The reform reshapes incentives around data protection periods, paediatric and rare-disease development, and environmental risk assessment, and no single authority holds all the expertise required to police those areas at once.
The adopted acts are expected to enter into force during 2026, with a transition period running to 2028. That runway matters, because the industry needs predictability and regulators need time to retool. Companies have spent years warning that Europe was losing ground to the United States and Asia in attracting clinical research and manufacturing investment, and the reform’s defenders argue that quicker, more transparent assessments are precisely what is needed to reverse that drift. Critics counter that trimming data protection could weaken the commercial case for developing medicines in Europe at all, a tension the legislation never fully resolved.
The agency is also moving on transparency. From 12 June, a beta version of a public application programming interface began making additional medicines data accessible in structured, machine-readable form, a modest but telling step toward letting researchers and watchdogs interrogate the regulatory record directly. Coupled with more than 14,000 clinical trial applications submitted under the Clinical Trials Regulation since 2022, and a proposed Biotech Act that would further overhaul the trials system, the direction of travel is clear: a more open, faster, more digital regulator.
What remains uncertain is whether ambition will survive contact with capacity. Shorter timelines do not create extra assessors, and the network model only works if national authorities are willing and funded to contribute staff already stretched by existing workloads. The risk is a two-speed system in which well-resourced agencies carry the load while others coast, eroding the mutual trust on which the single market for medicines depends.
For now, the message from the June meeting is one of cautious momentum. The legal architecture is taking shape, the agency is rewiring its processes, and a transition period offers a buffer against chaos. The harder questions, about funding, expertise and whether faster really means better, will only be answered once the new clocks start ticking on real applications.
